AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17632164 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg dutasteride daily
Number of subjects: 5597
Study 17632164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5597
Study 16214599 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG revaccination
Number of subjects: 348139
Study 16214599 — intervention group
Group type: COMPARATOR
Intervention: No revaccination (Control)
Number of subjects: 348139
Study 12123409 — intervention group
Group type: EXPERIMENTAL
Intervention: Low MAP goal (92 mm Hg or less)
Number of subjects: 1094
Study 12123409 — intervention group
Group type: COMPARATOR
Intervention: Usual MAP goal (102 to 107 mm Hg)
Number of subjects: 1094
Study 10654116 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Family Management with Standard Dose medication (BFMSD)
Number of subjects: 51
Study 10654116 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Family Management with Targeted Medication (BFMTM)
Number of subjects: 51
Study 7966893 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified split‐virion vaccine (n = 927)
Number of subjects: 1838
Study 7966893 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular placebo (n = 911)
Number of subjects: 1838
Study 3426975 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained doctors (communication skills programme)
Number of subjects: 0
Study 3426975 — intervention group
Group type: COMPARATOR
Intervention: Untrained general practitioners
Number of subjects: 0
Study 29788791 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard transdermal nicotine (nicotine replacement therapy)
Number of subjects: 499
Study 29788791 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended nicotine replacement therapy + adjunct nicotine agent
Number of subjects: 499
Study 29788791 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 499
Study 29788791 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 499
Study 26755405 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilization exercises plus manual therapy
Number of subjects: 102
Study 26755405 — intervention group
Group type: COMPARATOR
Intervention: Stabilization exercises alone
Number of subjects: 102
Study 24894701 — intervention group
Group type: EXPERIMENTAL
Intervention: 3'‐aminomethylnicotine Pseudomonas aeruginosa r‐Exoprotein‐conjugated vaccine (400 μg/ml)
Number of subjects: 48
Study 24894701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 22680238 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop stimulation (CLS)
Number of subjects: 36
Study 20160441 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g dentifrice containing 1,100 microg/g fluoride
Number of subjects: 0
Study 20160441 — intervention group
Group type: COMPARATOR
Intervention: 0.5 g dentifrice containing 1,100 microg/g fluoride
Number of subjects: 0
Study 20160441 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing time of 30, 45, 60, 120, and 180 seconds with 1.5 g dentifrice
Number of subjects: 0
Study 19019662 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.1 mg/kg bolus, 0.04 mg/kg/hr continuous, adjusted every 2 hours)
Number of subjects: 22
Study 19019662 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.625 microg kg(‐1) hr(‐1))
Number of subjects: 22
Study 19019662 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 22
Study 15818694 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg twice weekly) for 1 year
Number of subjects: 40
Study 15818694 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months before switching to etanercept
Number of subjects: 40
Study 12463111 — intervention group
Group type: EXPERIMENTAL
Intervention: 64 grams/day of walnuts in conjunction with the low-fat, low-cholesterol diet
Number of subjects: 67
Study 12463111 — intervention group
Group type: COMPARATOR
Intervention: Low-fat, low-cholesterol diet without walnuts
Number of subjects: 67
Study 10516937 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg tacrolimus capsules
Number of subjects: 32
Study 10516937 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg tacrolimus capsules
Number of subjects: 32
Study 10516937 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg tacrolimus doses administered at 7-day intervals
Number of subjects: 32
Study 8880373 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrodermal lability in hypertensive group
Number of subjects: 39
Study 8880373 — intervention group
Group type: COMPARATOR
Intervention: Control group (normotensive)
Number of subjects: 39
Study 2060560 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexfenfluramine 30 mg per day for 4 days
Number of subjects: 17
Study 6834501 — intervention group
Group type: EXPERIMENTAL
Intervention: Meatal care with poly-antibiotic ointment twice daily
Number of subjects: 428
Study 6834501 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 428
Study 6834501 — intervention group
Group type: EXPERIMENTAL
Intervention: Meatal care with poly-antibiotic ointment
Number of subjects: 428
Study 6834501 — intervention group
Group type: EXPERIMENTAL
Intervention: Meatal care with poly-antibiotic ointment in high-risk female patients
Number of subjects: 428
Study 31892661 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing exercise programme in addition to usual care (BrEX + UC)
Number of subjects: 190
Study 31892661 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) alone
Number of subjects: 190
Study 27589017 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking Away from Type 2 Diabetes intervention group
Number of subjects: 808
Study 27589017 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 808
Study 27445317 — intervention group
Group type: EXPERIMENTAL
Intervention: High cut-off (HCO) dialysis
Number of subjects: 43
Study 27445317 — intervention group
Group type: COMPARATOR
Intervention: High-flux dialysis
Number of subjects: 43
Study 24718885 — intervention group
Group type: EXPERIMENTAL
Intervention: XELOX (capecitabine plus oxaliplatin)
Number of subjects: 113
Study 24718885 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 113
Study 22433499 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention plus usual care
Number of subjects: 0
Study 22433499 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 0
Study 19435491 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (IT) following screening
Number of subjects: 63
Study 19435491 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine care (RC) following screening
Number of subjects: 63
Study 19435491 — intervention group
Group type: COMPARATOR
Intervention: No screening (control)
Number of subjects: 63
Study 19435491 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (IT)
Number of subjects: 63
Study 19435491 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine care (RC)
Number of subjects: 63
Study 19435491 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening programme
Number of subjects: 63
Study 17264015 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity model training (n = 14)
Number of subjects: 27
Study 17264015 — intervention group
Group type: COMPARATOR
Intervention: Low-fidelity model training (n = 13)
Number of subjects: 27
Study 15095072 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Training (HIT)
Number of subjects: 81
Study 15095072 — intervention group
Group type: COMPARATOR
Intervention: Low-Intensity Training (LIT)
Number of subjects: 81
Study 11266417 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg/24 h for 3 days)
Number of subjects: 118
Study 11266417 — intervention group
Group type: COMPARATOR
Intervention: Co-amoxiclav (45/11.25 mg/kg/24 h for 10 days)
Number of subjects: 118
Study 9835466 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous buffered lidocaine (SQBL)
Number of subjects: 103
Study 9835466 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous normal saline with 0.9% benzyl alcohol (SQNS)
Number of subjects: 103
Study 9835466 — intervention group
Group type: COMPARATOR
Intervention: No pretreatment (NPTx)
Number of subjects: 103
Study 7656458 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic lupus erythematosus patients (16-59 years)
Number of subjects: 40
Study 7656458 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic lupus erythematosus patients (16-29 years)
Number of subjects: 40
Study 7656458 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic lupus erythematosus patients (60-69 years)
Number of subjects: 40
Study 7656458 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 40
Study 2180337 — intervention group
Group type: EXPERIMENTAL
Intervention: Early cholecystectomy
Number of subjects: 269
Study 2180337 — intervention group
Group type: COMPARATOR
Intervention: Delayed cholecystectomy
Number of subjects: 269
Study 7001488 — intervention group
Group type: EXPERIMENTAL
Intervention: Silderm (triamcinolone acetonide, neomycin sulphate, undecenoic acid)
Number of subjects: 52
Study 7001488 — intervention group
Group type: COMPARATOR
Intervention: Other cream (triamcinolone acetonide, neomycin sulphate, nystatin, gramicidin)
Number of subjects: 52
Study 30521040 — intervention group
Group type: EXPERIMENTAL
Intervention: CEASE intervention
Number of subjects: 10
Study 30521040 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 10
Study 31557945 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) 3 mg/kg/body mass
Number of subjects: 8
Study 31557945 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) psychology (given PLA/told CAF)
Number of subjects: 8
Study 31557945 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) pharmacology
Number of subjects: 8
Study 31557945 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 8
Study 28641153 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg for 24 months
Number of subjects: 915
Study 28641153 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 80 mg for 24 months
Number of subjects: 915
Study 25977821 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive surgical eradication of atypical breast lesions (specific intervention details such as dosage and duration are not available)
Number of subjects: 0
Study 25977821 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery and radiation for DCIS
Number of subjects: 0
Study 23735736 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance-based financing (PBF) scheme for MNCH services
Number of subjects: 0
Study 23735736 — intervention group
Group type: COMPARATOR
Intervention: Technical assistance
Number of subjects: 0
Study 21392177 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin levels assessment in alcohol-dependent subjects
Number of subjects: 0
Study 21392177 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline ghrelin levels
Number of subjects: 0
Study 21392177 — intervention group
Group type: COMPARATOR
Intervention: Ghrelin gene polymorphisms (Arg51Gln and Leu72Met) assessment
Number of subjects: 0
Study 19686917 — intervention group
Group type: EXPERIMENTAL
Intervention: Marginal flap
Number of subjects: 31
Study 19686917 — intervention group
Group type: COMPARATOR
Intervention: Paramarginal flap
Number of subjects: 31
Study 17454969 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion-focused coping
Number of subjects: 553
Study 17454969 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-focused coping
Number of subjects: 553
Study 15850317 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin (120 U/kg, up to 10,000 U)
Number of subjects: 100
Study 15850317 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 100
Study 15850317 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 100
Study 11587680 — intervention group
Group type: EXPERIMENTAL
Intervention: Nissen fundoplication with division of short gastric vessels (SGV)
Number of subjects: 56
Study 11587680 — intervention group
Group type: COMPARATOR
Intervention: Nissen fundoplication without division of short gastric vessels (SGV)
Number of subjects: 56
Study 9638988 — intervention group
Group type: EXPERIMENTAL
Intervention: All trans retinoic acid (ATRA) 45 mg/M2/day for 90 days followed by 90 mg/M2 on alternate days till Day 275, combined with low dose cytosine arabinoside (Ara‐C) 10 mg/m2 subcutaneously twice daily for 21 days for a total of 6 cycles.
Number of subjects: 10
Study 8078983 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptylinoxide (120-360 mg daily for 4 weeks)
Number of subjects: 44
Study 8078983 — intervention group
Group type: COMPARATOR
Intervention: Doxepine (120-360 mg daily for 4 weeks)
Number of subjects: 44
Study 8078983 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Amitriptylinoxide and Doxepine)
Number of subjects: 44
Study 2737231 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethicone
Number of subjects: 10
Study 2737231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30514196 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (1000 IU) for 2 weeks in addition to daily subcutaneous human recombinant erythropoietin (2500 IU/kg) for 5 days and IM or IV magnesium sulphate 250 mg/kg within half an hour of birth, subsequently 125 mg/kg at 24 and 48 hours of life.
Number of subjects: 60
Study 30514196 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin and magnesium sulphate as in group I but without vitamin D.
Number of subjects: 60
Study 30514196 — intervention group
Group type: COMPARATOR
Intervention: Control group (30 healthy neonates).
Number of subjects: 60
Study 28191917 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency-management approach
Number of subjects: 35
Study 28191917 — intervention group
Group type: COMPARATOR
Intervention: Standard care arm
Number of subjects: 35
Study 25968593 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls (n = 167)
Number of subjects: 335
Study 25968593 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-pubertal boys (n = 83)
Number of subjects: 335
Study 25968593 — intervention group
Group type: COMPARATOR
Intervention: Pubertal boys (n = 85)
Number of subjects: 335
Study 23767801 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian latent group model
Number of subjects: 0
Study 21170708 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitatory transcranial direct current stimulation (tDCS) applied over the lesioned hemisphere
Number of subjects: 0
Study 21170708 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation over the lesioned hemisphere
Number of subjects: 0
Study 21170708 — intervention group
Group type: COMPARATOR
Intervention: tDCS applied over the non-lesioned hemisphere
Number of subjects: 0
Study 19101739 — intervention group
Group type: EXPERIMENTAL
Intervention: ART (Atraumatic Restorative Treatment)
Number of subjects: 327
Study 19101739 — intervention group
Group type: COMPARATOR
Intervention: ART with Carisolv (chemomechanical caries removal gel)
Number of subjects: 327
Study 17239474 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (RSG) 4mg daily (increased to 8mg for some subjects)
Number of subjects: 40
Study 17239474 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (IG) 10 units daily (doses increased until fasting glucose <120mg/dl)
Number of subjects: 40
Study 14963058 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein diet (at least 20 g) and isoflavones (at least 80 mg) for 5 weeks
Number of subjects: 61
Study 14963058 — intervention group
Group type: COMPARATOR
Intervention: Olive oil containing active placebo diet
Number of subjects: 61
Study 14963058 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (soy protein and placebo)
Number of subjects: 61
Study 11758227 — intervention group
Group type: EXPERIMENTAL
Intervention: Lupus anticoagulant (LA) IgG from SLE patients
Number of subjects: 0
Study 11758227 — intervention group
Group type: COMPARATOR
Intervention: Normal IgG
Number of subjects: 0
Study 9412880 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (2 x 10(6) kallikrein inhibitor units in CPB prime)
Number of subjects: 43
Study 9412880 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated group)
Number of subjects: 43
Study 8118564 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical surgery
Number of subjects: 144
Study 8118564 — intervention group
Group type: EXPERIMENTAL
Intervention: External-beam radiation
Number of subjects: 144
Study 8118564 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 144
Study 3085551 — intervention group
Group type: EXPERIMENTAL
Intervention: nalbuphine (0.21 mg/kg, intravenous)
Number of subjects: 12
Study 3085551 — intervention group
Group type: EXPERIMENTAL
Intervention: naloxone (0.014 mg/kg, intravenous)
Number of subjects: 12
Study 3085551 — intervention group
Group type: COMPARATOR
Intervention: placebo (normal saline)
Number of subjects: 12
Study 31246234 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate, 1000 mg, once daily with prednisone, 5 mg, twice daily
Number of subjects: 164
Study 31246234 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate, 1000 mg, once daily with prednisone, 5 mg, once daily
Number of subjects: 164
Study 31246234 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate, 1000 mg, once daily with prednisone, 2.5 mg, twice daily
Number of subjects: 164
Study 31246234 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate, 1000 mg, once daily with dexamethasone, 0.5 mg, once daily
Number of subjects: 164
Study 30466438 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandolean® training
Number of subjects: 24
Study 30466438 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 24
Study 26894653 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg febuxostat twice daily
Number of subjects: 96
Study 26894653 — intervention group
Group type: EXPERIMENTAL
Intervention: 40/80 mg febuxostat once daily
Number of subjects: 96
Study 26894653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 24876915 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine with McDonald's Meal (McD)
Number of subjects: 24
Study 24876915 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine with Mediterranean Meal (MM)
Number of subjects: 24
Study 24876915 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting with red wine
Number of subjects: 24
Study 24876915 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions with red wine
Number of subjects: 24
Study 24876915 — intervention group
Group type: COMPARATOR
Intervention: McDonald's Meal (McD) without red wine
Number of subjects: 24
Study 24876915 — intervention group
Group type: COMPARATOR
Intervention: Mediterranean Meal (MM) without red wine
Number of subjects: 24
Study 23338259 — intervention group
Group type: EXPERIMENTAL
Intervention: Single‐Bond 2 (Sb2)
Number of subjects: 80
Study 23338259 — intervention group
Group type: EXPERIMENTAL
Intervention: Single‐Bond 2 + Bond/Scotchbond‐Multipurpose (Sb2B)
Number of subjects: 80
Study 23338259 — intervention group
Group type: EXPERIMENTAL
Intervention: Single‐Bond 2 + Filtek‐Flow Z350 (Sb2Fl)
Number of subjects: 80
Study 23338259 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond‐Multipurpose (SBMP)
Number of subjects: 80
Study 23338259 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil‐S3 (CS3)
Number of subjects: 80
Study 23338259 — intervention group
Group type: EXPERIMENTAL
Intervention: CS3 + Bond/Clearfil‐SE Bond (CSE3B)
Number of subjects: 80
Study 23338259 — intervention group
Group type: EXPERIMENTAL
Intervention: CS3 + Protect Liner F (CS3PL)
Number of subjects: 80
Study 23338259 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond + Protect Liner F (CSEBPL)
Number of subjects: 80
Study 23338259 — intervention group
Group type: COMPARATOR
Intervention: (Control group not specified)
Number of subjects: 80
Study 20186380 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavyweight mesh (P group)
Number of subjects: 50
Study 20186380 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightweight mesh (NK group)
Number of subjects: 50
Study 20186380 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 50
Study 17918559 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced cardiovascular exercise (20 min at approximately 65% maximal heart rate)
Number of subjects: 72
Study 17918559 — intervention group
Group type: COMPARATOR
Intervention: Standard cardiovascular exercise (30 min at approximately 80% maximal heart rate)
Number of subjects: 72
Study 15640324 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral L-arginine supplementation (200 mg x kg(‐1) body weight, t.i.d. for 6 weeks)
Number of subjects: 10
Study 15640324 — intervention group
Group type: COMPARATOR
Intervention: Single dose of oral L-arginine (200 mg x kg(‐1) body weight)
Number of subjects: 10
Study 11972568 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultural and self-empowerment group (five-phased intervention)
Number of subjects: 0
Study 11972568 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified cultural group (phase I of the intervention only)
Number of subjects: 0
Study 11972568 — intervention group
Group type: COMPARATOR
Intervention: Traditional group (control group)
Number of subjects: 0
Study 10456484 — intervention group
Group type: EXPERIMENTAL
Intervention: (R)-salbutamol
Number of subjects: 33
Study 10456484 — intervention group
Group type: EXPERIMENTAL
Intervention: rac-salbutamol
Number of subjects: 33
Study 10456484 — intervention group
Group type: COMPARATOR
Intervention: (S)-salbutamol
Number of subjects: 33
Study 8679032 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression ultrasound screening before and after arthroscopic surgery
Number of subjects: 85
Study 8679032 — intervention group
Group type: COMPARATOR
Intervention: Patients with DVT risk factors
Number of subjects: 85
Study 1369702 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 30 mg t.i.d. for 2 weeks
Number of subjects: 8
Study 1369702 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine at various concentrations (10 nM, 1 microM, 10 mM)
Number of subjects: 8
Study 36817 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine, 300 mg IV, 2 hr before induction of anesthesia
Number of subjects: 23